Associations - ERBB4 (erb-b2 receptor tyrosine kinase 4)

ERBB4 G668V	Lung Non-Small Cell Squamous Cancer	ERBB4 G668V	Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
ERBB4 mutation	Melanoma	ERBB4 mutation	Melanoma	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
ERBB4 expression	HER2 Positive Breast Cancer	ERBB4 expression	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
ERBB4 mutation + HER-2 positive	Gastric Cancer	ERBB4 mutation + HER-2 positive	Gastric Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
ERBB4 mutation	Non Small Cell Lung Cancer	ERBB4 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ERBB4 H809G + ER positive	HER2 Positive Breast Cancer	ERBB4 H809G + ER positive	HER2 Positive Breast Cancer	lapatinib Resistant: C4 – Case Studies lapatinib Resistant : C4	lapatinib Resistant: C4 – Case Studies lapatinib Resistant : C4
TERT mutation + ERBB4 mutation	Colon Cancer	TERT mutation + ERBB4 mutation	Colon Cancer	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4
ERBB4 G1109C	Head and Neck Cancer	ERBB4 G1109C	Head and Neck Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
ERBB4 G1109C	Esophageal Cancer	ERBB4 G1109C	Esophageal Cancer	erlotinib Resistant: D – Preclinical erlotinib Resistant : D	erlotinib Resistant: D – Preclinical erlotinib Resistant : D
ERBB4 G1109C	Esophageal Cancer	ERBB4 G1109C	Esophageal Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D
ERBB4 G1109C	Esophageal Cancer	ERBB4 G1109C	Esophageal Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
ERBB4 G1109C	Squamous Cell Carcinoma of Head and Neck	ERBB4 G1109C	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D

ERBB4 (erb-b2 receptor tyrosine kinase 4)

Associations(12)

Associations
(12)